CEVA-101 (pediatric & adult)
Traumatic Brain Injury (TBI)
Phase 2Active
Key Facts
About Fortress Biotech
Fortress Biotech operates as a biopharmaceutical accelerator, utilizing a flexible, therapeutic area-agnostic model to identify and advance high-potential assets. The company has achieved significant milestones, including the FDA approval of ZYCUBO® for Menkes disease and the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million. By developing products both internally and through a network of majority-owned and minority partner companies, Fortress aims to create a diversified, long-term revenue stream from commercial products, royalties, and equity stakes.
View full company profileTherapeutic Areas
Other Traumatic Brain Injury (TBI) Drugs
| Drug | Company | Phase |
|---|---|---|
| CEVA-102 | Fortress Biotech | Preclinical |
| Unnamed programs | Astrocyte Pharmaceuticals | Preclinical |